{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:42:43Z","timestamp":1791499363839,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>To report real-world clinical experience with [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA-I&amp;T targeted radionuclide therapy (TRT) in patients with metastatic castration-resistant prostate cancer (mCRPC) in a single tertiary referral university hospital.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients with mCRPC who were treated with [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA-I&amp;T TRT as standard of care between February 2022 and August 2023 were included in this retrospective study. Patients were treated with a maximum of six cycles with a fixed activity of 7.4 GBq\/100\u00b5g [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA-I&amp;T per cycle.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>50 patients with mCRPC were included, of them 84% had prior therapy with two lines of taxane-based chemotherapy treated and at least one line of androgen receptor signaling inhibitor. A total of 126 cycles with a median of 2 cycles (IQR 1\u20136) [ <jats:sup>177<\/jats:sup>Lu]Lu-PSMA-I&amp;T were administered per patient. PSA declines of \u2265\u200950% and \u2265\u200970% were achieved in 16% and 10% of the patients, respectively. Radiological response was achieved in 11% of the patients. In total, 68 treatment-related Adverse Events (TRAEs) were observed, mainly grade 1\u20132 in 88% of cases. Grade 3\/4 TRAEs were observed in 12% of cases. No grade 3 or higher xerostomia was reported. Median progression-free survival was 7.7 months (95% CI 4.0-11.3) and median overall survival was 8.1 months (95% CI 5.0-11.3).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In heavily pretreated patients with mCRPC, treatment of [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA-I&amp;T TRT is well tolerated and safe, but real-world efficacy of [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA appears lower compared to data from recent phase-3 clinical trials using a different radioligand [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA-617. Further studies may show whether patients with mCRPC benefit more from [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA when initiated at an earlier stage of treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00259-025-07082-9","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T02:51:14Z","timestamp":1737168674000},"page":"2034-2040","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["First real-world clinical experience with [177Lu]Lu-PSMA-I&amp;T in patients with metastatic castration-resistant prostate cancer beyond VISION and TheraP criteria"],"prefix":"10.1007","volume":"52","author":[{"given":"Sui wai","family":"Ling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quido","family":"de Lussanet de la Sabloni\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ananta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"de Blois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn L. W.","family":"Koolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roosmarijn C.","family":"Drexhage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Hofland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie G. J.","family":"Robbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid A M","family":"van der Veldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik A","family":"Verburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8000-6490","authenticated-orcid":false,"given":"Tessa","family":"Brabander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,18]]},"reference":[{"issue":"2","key":"7082_CR1","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41391-020-00299-9","volume":"24","author":"MK Labriola","year":"2021","unstructured":"Labriola MK, Atiq S, Hirshman N, Bitting RL. Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies. Prostate Cancer Prostatic Dis. 2021;24(2):301\u20139.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"7082_CR2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/MOU.0000000000000685","volume":"30","author":"IO Lawal","year":"2020","unstructured":"Lawal IO, Bruchertseifer F, Vorster M, Morgenstern A, Sathekge MM. Prostate-specific membrane antigen-targeted endoradiotherapy in metastatic prostate cancer. Curr Opin Urol. 2020;30(1):98\u2013105.","journal-title":"Curr Opin Urol"},{"issue":"4","key":"7082_CR3","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"P Cornford","year":"2017","unstructured":"Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate Cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate Cancer. Eur Urol. 2017;71(4):630\u201342.","journal-title":"Eur Urol"},{"issue":"12","key":"7082_CR4","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate Cancer. N Engl J Med. 2021;385(12):1091\u2013103.","journal-title":"N Engl J Med"},{"issue":"10276","key":"7082_CR5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797\u2013804.","journal-title":"Lancet"},{"key":"7082_CR6","unstructured":"Agency EM. PLUVICTO - Lutetium (177Lu) vipivotide tetraxetan [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/pluvicto-epar-product-information_en.pdf"},{"issue":"9","key":"7082_CR7","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1007\/s00259-022-05744-6","volume":"49","author":"PE Hartrampf","year":"2022","unstructured":"Hartrampf PE, Weinzierl FX, Buck AK, Rowe SP, Higuchi T, Seitz AK, et al. Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2022;49(9):3269\u201376.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"7082_CR8","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","volume":"50","author":"C Kratochwil","year":"2023","unstructured":"Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, et al. Joint EANM\/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023;50(9):2830\u201345.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"7082_CR9","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1007\/s00259-021-05661-0","volume":"49","author":"BM Prive","year":"2022","unstructured":"Prive BM, Derks YHW, Rosar F, Franssen GM, Peters SMB, Khreish F, et al. (89)Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man. Eur J Nucl Med Mol Imaging. 2022;49(6):2064\u201376.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"7082_CR10","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2967\/jnumed.121.262713","volume":"63","author":"C Schuchardt","year":"2022","unstructured":"Schuchardt C, Zhang J, Kulkarni HR, Chen X, Muller D, Baum RP. Prostate-specific membrane Antigen Radioligand Therapy using (177)Lu-PSMA I&T and (177)Lu-PSMA-617 in patients with metastatic castration-resistant prostate Cancer: comparison of Safety, Biodistribution, and Dosimetry. J Nucl Med. 2022;63(8):1199\u2013207.","journal-title":"J Nucl Med"},{"issue":"1","key":"7082_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s41181-022-00181-0","volume":"7","author":"EL Hooijman","year":"2022","unstructured":"Hooijman EL, Ntihabose CM, Reuvers TGA, Nonnekens J, Aalbersberg EA, van de Merbel J, et al. Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC\/HPLC analysis, demonstrated by [(177)Lu]Lu-PSMA. EJNMMI Radiopharm Chem. 2022;7(1):29.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"2","key":"7082_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-Dotatate for Midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335.","journal-title":"N Engl J Med"},{"issue":"12","key":"7082_CR13","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, et al. (177)Lu-Dotatate plus long-acting octreotide versus high\u2013dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1752\u201363.","journal-title":"Lancet Oncol"},{"issue":"2","key":"7082_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"8","key":"7082_CR15","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.2967\/jnumed.124.267452","volume":"65","author":"Z Ells","year":"2024","unstructured":"Ells Z, Grogan TR, Czernin J, Dahlbom M, Calais J. Dosimetry of [(177)Lu]Lu-PSMA-Targeted Radiopharmaceutical therapies in patients with prostate Cancer: a comparative systematic review and metaanalysis. J Nucl Med. 2024;65(8):1264\u201371.","journal-title":"J Nucl Med"},{"key":"7082_CR16","doi-asserted-by":"crossref","unstructured":"Ling SW, de Blois E, Hooijman E, van der Veldt A, Brabander T. Advances in (177)Lu-PSMA and (225)Ac-PSMA Radionuclide Therapy for metastatic castration-resistant prostate Cancer. Pharmaceutics. 2022;14(10).","DOI":"10.3390\/pharmaceutics14102166"},{"issue":"16suppl","key":"7082_CR17","first-page":"e17061","volume":"42","author":"M Vishnu","year":"2024","unstructured":"Vishnu M, Andrew V, Kathleen N, Martin SA-A, Sydney C, Elisa ML, et al. Efficacy and toxicity of [177Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer in a real-world setting: results from the U.S. expanded Access Program and comparisons with phase 3 VISION data. J Clin Oncol. 2024;42(16suppl):e17061\u2013e.","journal-title":"J Clin Oncol"},{"issue":"15","key":"7082_CR18","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502\u201312.","journal-title":"N Engl J Med"},{"issue":"9747","key":"7082_CR19","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147\u201354.","journal-title":"Lancet"},{"issue":"12","key":"7082_CR20","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1007\/s00259-021-05383-3","volume":"48","author":"H Ahmadzadehfar","year":"2021","unstructured":"Ahmadzadehfar H, Matern R, Baum RP, Seifert R, Kessel K, Bogemann M, et al. The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [(177)Lu]Lu-PSMA-617: a WARMTH multicentre study. Eur J Nucl Med Mol Imaging. 2021;48(12):4067\u201376.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7082_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13550-021-00805-7","volume":"11","author":"D Groener","year":"2021","unstructured":"Groener D, Nguyen CT, Baumgarten J, Bockisch B, Davis K, Happel C, et al. Hematologic safety of (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. EJNMMI Res. 2021;11(1):61.","journal-title":"EJNMMI Res"},{"issue":"4","key":"7082_CR22","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","volume":"76","author":"A Paschalis","year":"2019","unstructured":"Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, et al. Prostate-specific membrane Antigen Heterogeneity and DNA repair defects in prostate Cancer. Eur Urol. 2019;76(4):469\u201378.","journal-title":"Eur Urol"},{"issue":"13","key":"7082_CR23","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1158\/1078-0432.CCR-20-4298","volume":"27","author":"BM Prive","year":"2021","unstructured":"Prive BM, Peters SMB, Muselaers CHJ, van Oort IM, Janssen MJR, Sedelaar JPM, et al. Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate Cancer: a prospective pilot study. Clin Cancer Res. 2021;27(13):3595\u2013601.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"7082_CR24","doi-asserted-by":"publisher","first-page":"e564","DOI":"10.1097\/RLU.0000000000004901","volume":"48","author":"MO Demirkol","year":"2023","unstructured":"Demirkol MO, Esen B, Seymen H, Sen M, Ucar B, Kurtuldu S, et al. Radioligand Therapy with 177 Lu-PSMA-I&T in patients with metastatic prostate Cancer: Oncological outcomes and Toxicity Profile. Clin Nucl Med. 2023;48(12):e564\u20139.","journal-title":"Clin Nucl Med"},{"issue":"11","key":"7082_CR25","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.2967\/jnumed.123.265878","volume":"64","author":"A Karimzadeh","year":"2023","unstructured":"Karimzadeh A, Soeiro P, Feuerecker B, Hecker CS, Knorr K, Heck MM, et al. Improved quality of life in metastatic castration-resistant prostate Cancer patients receiving consecutive cycles of (177)Lu-PSMA I&T. J Nucl Med. 2023;64(11):1765\u201371.","journal-title":"J Nucl Med"},{"issue":"12","key":"7082_CR26","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1007\/s00259-022-05853-2","volume":"49","author":"PE Hartrampf","year":"2022","unstructured":"Hartrampf PE, Seitz AK, Weinzierl FX, Serfling SE, Schirbel A, Rowe SP, et al. Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [(177)Lu]Lu-PSMA I&T during long-term follow-up. Eur J Nucl Med Mol Imaging. 2022;49(12):4262\u201370.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7082_CR27","doi-asserted-by":"publisher","first-page":"175883592311563","DOI":"10.1177\/17588359231156392","volume":"15","author":"L Emmett","year":"2023","unstructured":"Emmett L, John N, Pathmanandavel S, Counter W, Ayers M, Sharma S, et al. Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT). Ther Adv Med Oncol. 2023;15:17588359231156392.","journal-title":"Ther Adv Med Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07082-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07082-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07082-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T10:26:39Z","timestamp":1745317599000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07082-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,18]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["7082"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07082-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,18]]},"assertion":[{"value":"1 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Erasmus Medical Center (15 March 2024\/MEC-2024-0104).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent from all individual participants included in the study was waived by the Ethics Committee of the Erasmus Medical Center under special circumstances.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}